Bayer submits application for next indication of Kerendia in China
Berlin, July 30, 2026 – Bayer today announced the submission of a New Drug Application to the Center…
European Medicines Agency confirms Bayer’s FXIa inhibitor marketing authorization application for assessment in secondary prevention of ischemic stroke
Not intended for U.S. and UK Media European Medicines Agency confirms asundexian marketing authorization application for assessment…
Bayer’s low-dose MRI contrast agent approved in U.S.
Not intended for U.S. and UK Media Bayer’s low-dose MRI contrast agent gadoquatrane approved in U.S. …
Bayer and Kumquat Biosciences enter global exclusive license and collaboration in precision oncology
Berlin, Germany and San Diego, USA, August 12, 2025 – Bayer and Kumquat Biosciences Inc., a clinical-stage biotech…
Finerenone meets primary endpoint in pivotal Phase III FIND-CKD study in patients with non-diabetic chronic kidney disease
Berlin, March 16, 2026 – The Phase III study FIND-CKD, evaluating the efficacy and safety of finerenone (Kerendia™)…
Phase III study results with Bayer’s FXIa inhibitor demonstrating substantial reduction in ischemic stroke with no increase in ISTH major bleeding versus placebo published in New England Journal of Medicine
Berlin, April 16, 2026 – Bayer today announced the publication of the full results from the global, pivotal…
Bayer receives Breakthrough Therapy Designation in the U.S. and China for sevabertinib as a first-line treatment for patients with HER2-mutant non-small cell lung cancer
Berlin, January 6, 2026 – Bayer announced today that the U.S. Food and Drug Administration (FDA) and the…
Finerenone approved in Japan for treatment of patients with chronic heart failure
Berlin, December 22, 2025 – Bayer today announced that Japan’s Ministry of Health, Labour and Welfare (MHLW) has…
Bayer to Present New Phase III Data and Advancements of Radiology Portfolio at ECR 2026
Berlin, January 26, 2026 – Bayer will present advancements of its comprehensive radiology portfolio at the 2026 European…
First approval for Bayer’s low-dose MRI contrast agent in Japan
Not intended for U.S. and UK Media First approval for Bayer’s low-dose MRI contrast agent Ambelvist™ (gadoquatrane) in…
China’s Center of Drug Evaluation grants Priority Review designation for Bayer’s FXIa inhibitor
Not intended for U.S. and UK Media China’s Center of Drug Evaluation grants Priority Review designation for asundexian …
New drug applications for Bayer’s FXIa inhibitor accepted by U.S. Food and Drug Administration under Priority Review and by Japan’s Ministry of Health, Labour and Welfare
Berlin, May 19, 2026 – Bayer today announced that the U.S. Food and Drug Administration (FDA) and Japan’s…